These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 28139087)

  • 21. Addressing the need for economic evaluation of cardiovascular medical devices in India.
    Masurkar PP
    Curr Probl Cardiol; 2024 Aug; 49(8):102677. PubMed ID: 38795804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports.
    Taylor RS; Elston J
    Health Technol Assess; 2009 Jan; 13(8):iii, ix-xi, 1-50. PubMed ID: 19203465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Barriers and facilitators of patient access to medical devices in Europe: A systematic literature review.
    Beck A; Retèl VP; Bhairosing PA; van den Brekel M; van Harten WH
    Health Policy; 2019 Dec; 123(12):1185-1198. PubMed ID: 31718855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs.
    Rothery C; Claxton K; Palmer S; Epstein D; Tarricone R; Sculpher M
    Health Econ; 2017 Feb; 26 Suppl 1():109-123. PubMed ID: 28139090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union.
    Beletsi A; Koutrafouri V; Karampli E; Pavi E
    Value Health Reg Issues; 2018 Sep; 16():81-91. PubMed ID: 30316029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
    Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
    Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TAXONOMY OF MEDICAL DEVICES IN THE LOGIC OF HEALTH TECHNOLOGY ASSESSMENT.
    Henschke C; Panteli D; Perleth M; Busse R
    Int J Technol Assess Health Care; 2015 Jan; 31(5):324-30. PubMed ID: 26711471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
    Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
    Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors influencing coverage decisions on medical devices: A retrospective analysis of 78 medical device appraisals for the Austrian hospital benefit catalogue 2008-2015.
    Kisser A; Tüchler H; Erdös J; Wild C
    Health Policy; 2016 Aug; 120(8):903-12. PubMed ID: 27344197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions.
    Wang T; McAuslane N; Liberti L; Leufkens H; Hövels A
    Value Health; 2018 Jun; 21(6):707-714. PubMed ID: 29909876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HEALTH TECHNOLOGY ASSESSMENT OF MEDICAL DEVICES IN EUROPE: PROCESSES, PRACTICES, AND METHODS.
    Fuchs S; Olberg B; Panteli D; Busse R
    Int J Technol Assess Health Care; 2016 Jan; 32(4):246-255. PubMed ID: 27670589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA.
    Kristensen FB; Husereau D; Huić M; Drummond M; Berger ML; Bond K; Augustovski F; Booth A; Bridges JFP; Grimshaw J; IJzerman MJ; Jonsson E; Ollendorf DA; Rüther A; Siebert U; Sharma J; Wailoo A
    Value Health; 2019 Jan; 22(1):13-20. PubMed ID: 30661627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges.
    Daubner-Bendes R; Kovács S; Niewada M; Huic M; Drummond M; Ciani O; Blankart CR; Mandrik O; Torbica A; Yfantopoulos J; Petrova G; Holownia-Voloskova M; Taylor RS; Al M; Piniazhko O; Lorenzovici L; Tarricone R; Zemplényi A; Kaló Z
    Front Public Health; 2020; 8():612410. PubMed ID: 33490024
    [No Abstract]   [Full Text] [Related]  

  • 35. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
    Akehurst RL; Abadie E; Renaudin N; Sarkozy F
    Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.
    Bloem LT; Vreman RA; Peeters NWL; Hoekman J; van der Elst ME; Leufkens HGM; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
    Clin Transl Sci; 2021 Jul; 14(4):1566-1577. PubMed ID: 33786991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Use of MCDA in HTA: Great Potential, but More Effort Needed.
    Marsh KD; Sculpher M; Caro JJ; Tervonen T
    Value Health; 2018 Apr; 21(4):394-397. PubMed ID: 29680094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scientific Evidence in Health Technology Assessment Reports: An In-Depth Analysis of European Assessments on High-Risk Medical Devices.
    Olberg B; Fuchs S; Panteli D; Perleth M; Busse R
    Value Health; 2017 Dec; 20(10):1420-1426. PubMed ID: 29241902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [HTA goes Europe: European collaboration on joint assessment and methodological issues becomes reality].
    Nachtnebel A; Mayer J; Erdös J; Lampe K; Kleijnen S; Schnell-Inderst P; Wild C
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):291-9. PubMed ID: 26354129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group.
    Nestler-Parr S; Korchagina D; Toumi M; Pashos CL; Blanchette C; Molsen E; Morel T; Simoens S; Kaló Z; Gatermann R; Redekop W
    Value Health; 2018 May; 21(5):493-500. PubMed ID: 29753344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.